君實生物(01877.HK)授出特瑞普利單抗許可與商業化協議
君實生物(01877.HK)公布,與瑞迪博士實驗室(Reddy’s Laboratories)簽署許可與商業化協議。據此,公司向瑞迪博士實驗室授出許可,於巴西、墨西哥、哥倫比亞、阿根廷、秘魯、智利、巴拿馬、烏拉圭、印度及南非開發及獨佔地商業化特瑞普利單抗注射液(產品代號「TAB001/JS001」)。
根據協議,公司可獲得700萬美元的預付款以及用於潛在擴大至瑞迪博士實驗室區域2的300萬美元款項,並於約定的里程碑事件達成後,最多可獲得7.18億美元,外加含特瑞普利單抗注射液的產品銷售淨額兩位數百分比的特許權使用費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.